Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide with Radiation for Brain Metastases from NSCLC
NCT00034697Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2001
- Primary completion
- Jan 2003
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of temozolomide in brain metastases, non-small cell lung cancer (NSCLC), sponsored by Merck & Co.. Started Jun 2001; status: terminated.
02
Drugs
temozolomide
03
Conditions
brain metastasesnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00034697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00034697.